You are here: Industry Insights > TerSera

News List

QUZYTTIR™ shows promise in preventing infusion related reactions europeanpharmaceuticalreview
March 09, 2021
Phase II data suggests intravenous QUZYTTIR™ cetirizine hydrochloride can decrease infusion reactions to anti-CD20 antibody treatments and reduce time to discharge after therapy.
CDC adds cetirizine as therapy for anaphylaxis after Covid-19 vaccination pharmaceutical-technology
February 25, 2021
TerSera Therapeutics has announced the addition of cetirizine as adjunctive therapy to the Centers for Disease Control and Prevention (CDC) guidelines titled ‘Interim considerations: preparing for the potential management of anaphylaxis after Covid-19 ...
AstraZeneca and TerSera sign agreement to commercialise Zoladex in US and Canada pharmaceutical-technology
February 23, 2017
UK-based AstraZeneca has entered an agreement to sell the commercial rights for Zoladex (goserelin acetate implant) in the US and Canadian markets to pharmaceutical company TerSera Therapeutics.
AstraZeneca Enters Agreement with TerSera Therapeutics for Zoladex in the US and Canada americanpharmaceuticalreview
February 22, 2017
AstraZeneca has entered into an agreement with TerSera Therapeutics LLC (TerSera) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada. Zoladex is an injectable luteinising hormone-releasing hormone agonist,